Robert E. Rubin, M.D.; Harvey Gralnick, M.D.; Julian Niemetz, M.D.; Solomon Estren, M.D., F.A.C.P.; Louis E. Wasserman, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
The patient with hemophilia and a circulating anticoagulant often represents a grave medical emergency not responsive to therapy with fresh frozen plasma, since the anticoagulant blocks the action of antihemophiliac globulin (AHG). Concentrates of AHG of animal origin afford a therapeutic approach which has not been previously reported in this country.
We have studied four patients with circulating anticoagulants directed against AHG, three of whom were known hemophiliacs. The fourth did not have hemophilia, but, at age 62, was found to have a circulating anticoagulant directed against AHG. Three of these patients developed, at various times, severe life-threatening pharyngeal hemorrhages,
Rubin RE, Gralnick H, Niemetz J, et al. The Use of Animal AHG-Concentrates in Patients with Circulating Anticoagulants.. Ann Intern Med. 1966;64:1165. doi: 10.7326/0003-4819-64-5-1165_3
Download citation file:
Published: Ann Intern Med. 1966;64(5):1165.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use